MedTrace Logo

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

NCT03692403 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-08-18

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

Conditions

  • Endometriosis-related Pain

Interventions

DRUG

Quinagolide 360 µg

Vaginal ring containing quinagolide 360 µg for daily releases

DRUG

Quinagolide 720 µg

Vaginal ring containing quinagolide 720 µg for daily releases

DRUG

Quinagolide 1080 µg

Vaginal ring containing quinagolide 1080 µg for daily releases

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-26
Primary Completion
2022-02-14
Completion
2022-02-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692403 on ClinicalTrials.gov